Metabolic clearance rate of arginine vasopressin in severe chronic renal failure
Abstract
1. The metabolic clearance rate of arginine vasopressin was determined using a constant infusion technique in normal subjects and patients with chronic renal failure immediately before commencing dialysis. Endogenous arginine vasopressin was suppressed in all subjects before the infusion with a water load. 2. Plasma arginine vasopressin concentrations were determined using a sensitive and specific radioimmunoassay after Florisil extraction. The detection limit of the assay was 0.3 pmol/l, and intra- and inter-assay coefficients of variation at 2 pmol/l were 9.7% and 15.3%, respectively. 3. In normal subjects, the metabolic clearance rate was determined at two infusion rates producing steady-state concentrations of arginine vasopressin of 1.3 and 4.4 pmol/l. In the patients with renal failure, a single infusion rate was used, producing a steady-state concentration of 1.5 pmol/l. 4. At comparable plasma arginine vasopressin concentrations, metabolic clearance rate was significantly reduced in patients with renal failure (normal 1168 ± 235 ml/min versus renal failure 584 ± 169 ml/min; means ± sd; P<0.001). 5. Free water clearance was significantly reduced in normal subjects during the arginine vasopressin infusion from 8.19 ± 2.61 to −1.41 ± 0.51 ml/min (P<0.001), but was unchanged in the patients with renal failure after attaining comparable plasma arginine vasopressin concentrations. 6. In normal subjects there was a small but significant fall in metabolic clearance rate at the higher steady-state arginine vasopressin concentration (1168 ± 235 ml/min at 1.3 pmol/l versus 1059 ± 269 ml/min at 4.4 pmol/l; P = 0.016). 7. Our results show that the metabolic clearance rate of arginine vasopressin is reduced by approximately 50% in severe chronic renal failure. This alone may account for the raised plasma concentrations of the hormone seen in this condition.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with chronic renal failure, vasopressin clearance is much slower, with metabolic clearance rate reduced by approximately half, consistent with the conclusion that vasopressin is mainly cleared from the circulation through the kidneys.
“In patients with chronic renal failure, the clearance is much slower: MCR is reduced by approximately half 108, which is consistent with the conclusion that vasopressin is mainly cleared from the circulation through the kidneys.”
From Measuring Oxytocin and Vasopressin: Bioassays, Immunoassays and Random Numbers (2016) · cites this paper as [108]
Cited by
Sorted by citations
Measuring Oxytocin and Vasopressin: Bioassays, Immunoassays and Random Numbers
Leng, G., & Sabatier, N. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12413 · Cited by 237 · see citing works
“In patients with chronic renal failure, the clearance is much slower: MCR is reduced by approximately half (108), which is consistent with the conclusion that vasopressin is mainly cleared from the circulation through the kidneys.”
Forrest, P. (2001) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0102900503 · Cited by 54 · see citing works
Vasopressin administration facilitates fluid removal during hemodialysis
van der Zee, S., Thompson, A., Zimmerman, R., Lin, J. E., Huan, Y., Braskett, M., Sciacca, R. R., Landry, D. W., & Oliver, J. A. (2006) · Kidney International · doi:10.1038/sj.ki.5001885 · Cited by 49 · see citing works
Prolactin and Other Pituitary Disorders in Kidney Disease
Huang, W., & Molitch, M. E. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.03.010 · Cited by 26 · see citing works
Pharmacology of the Cardiovascular System
Sturgill, M. G., Kelly, M., & Notterman, D. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-07307-3.10025-4 · Cited by 15 · see citing works
Validation of an integrative mathematical model of dehydration and rehydration in virtual humans
Pruett, W. A., Clemmer, J. S., & Hester, R. L. (2016) · Physiological Reports · doi:10.14814/phy2.13015 · Cited by 9 · see citing works
“In a study of human patients beginning dialysis, plasma clearance rate was 50% lower than in healthy controls (Pruszczynski et al. 1984; Argent et al. 1992) suggesting that the kidney is responsible for about half of all clearance.”
BackgroundMolnár, A. H., Varga, C., Janáky, T., Tóth, G., Tóth, G., Farkas, J., László, F. A., & László, F. A. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2006.12.011 · Cited by 6 · see citing works
“The renal metabolic clearance rate for vasopressin decreases significantly if the plasma vasopressin concentration is high and the vasopressin receptor capacity becomes saturated [30,35].”
BackgroundPharmacology of the Cardiovascular System
Kelly, M., Sturgill, M. G., & Notterman, D. A. (2006) · Elsevier eBooks · doi:10.1016/b978-032301808-1.50026-2 · Cited by 3 · see citing works
Fluid and Electrolyte Problems in Chronic Kidney Disease
Kim, G. (2023) · Springer eBooks · doi:10.1007/978-3-031-42045-0_22 · Cited by 2 · see citing works
Arginine vasopressin disposition in the conscious rabbit
Lécrivain, A., Pichette, V., Ong, H., Homsy, W., & du Souich, P. (1996) · Peptides · doi:10.1016/0196-9781(95)02089-6 · Cited by 1 · see citing works
Hormonveränderungen bei Niereninsuffizienz und Leberzirrhose
Fenske, W. K. (2010) · Elsevier eBooks · doi:10.1016/b978-3-437-24680-7.10072-8
Other Pituitary Disorders and Kidney Disease
Huang, W., & Molitch, M. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_22
Trobaugh, K. A., Flannery, A. H., & Bastin, M. L. T. (2019) · ASHP eBooks · doi:10.37573/9781585285525.009
- Authors
- Argent, N. B., Wilkinson, R., & Baylis, P. H.
- Affiliations
- Newcastle University (GB)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 1992-11-01
- Volume
- 83
- Issue
- 5
- Pages
- 583-587
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2471006465
- Cited by
- 13
- References
- 0
- Citations by year
- 2023: 1 · 2021: 1 · 2019: 2 · 2016: 2
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Electrolyte and hormonal disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Keywords
- vasopressin, metabolic clearance rate, chronic kidney disease, free water clearance, vasopressin infusion, water load, plasma vasopressin concentration, dialysis
- MeSH terms
- Adolescent, Adult, Arginine Vasopressin, Female, Humans, Kidney, Kidney Failure, Chronic, Male, Metabolic Clearance Rate, Middle Aged, Water
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review